Besonderheiten in der therapie nicht-atherosklerotischer gefäßerkrankungen

Zeitschrift fur Arztliche Fortbildung und Qualitatssicherung

Volumn 93, Issue 9, 1999, Pages 645-649

  Schellong, Sebastian M ^a  

^a NONE

Author keywords

Connective tissue disease; Giant cell arteritis; Raynaud's phenomenon; Takaysu arteritis; Temporal arteritis; Thromboangiitis obliterans

Indexed keywords

ACETYLSALICYLIC ACID; ILOPROST; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E1;

AORTA ARCH SYNDROME; BUERGER DISEASE; DISEASE SEVERITY; GIANT CELL ARTERITIS; HUMAN; RAYNAUD PHENOMENON; REVASCULARIZATION; REVIEW; TEMPORAL ARTERITIS; TREATMENT INDICATION; VASCULAR DISEASE;

ARTERIAL OCCLUSIVE DISEASES; COMBINED MODALITY THERAPY; HUMANS; ISCHEMIA; LEG; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0033378690     PISSN: 14317621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bahlas S, Ramos-Remus C, Davis P (1998) Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 25: 99-104
2. Cerinic M M, Generini S, Pignone A (1997) New approaches to the treatment of Raynaud's phenomenon. Curr Opinion Rheumatol 9: 544-556
3. Creutzig A, Diehm D, Rieger H et al (1999) Thrombangiitis obliterans. In: Classen M, Dierkesmann R, Heimpel H et al. (ed) Rationelle Diagnostik und Therapie in der Inneren Medizin. München, Wien, Baltimore: Urban & Schwarzenberg E1 : 5-6
4. Creutzig A, Heidrich H, Podhaisky H (1999) Funktionelle Getäßerkrankungen. In: Classen M, Dierkesmann R, Heimpel H et al. (ed) Rationelle Dia gnostik und Therapie in der Inneren Medizin. München, Wien, Baltimore: Urban & Schwarzenberg E5: 1-2
5. Fiessinger J N, Schäfer M (1990) Trial of iloprost versus aspirin treatment for critical limb ischacmia of thromboangiitis obliterans. Lancet 335: 555-557
6. Hoffman G S, Leavitt R Y, Kerr G S et al (1994) Treatment of glucocortieoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37: 578-582
7. Kerr G S, Hallahan C W, Ciordano J et al (1994) Takayasu Arteritis. Ann Intern Med 120: 919-929
8. LaCivita L, Pitaro N, Rossi M (1996) Amlodipine in the treatment of Raynaud's phenomenon: a double blind placebo controlled crossover study. Clin Drug Invest 11 (suppl): 126-131
9. Largiadèr J, Schneider E, Brunner U et al (1986) Arterienkonstruktionen beim Morbus Buerger. Vasa 15(2): 174-179
10. Lie J T (1988) Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum 31:812-813
11. Moawad J, McKinsey J F, Wyble C W et al (1997) Current results of surgical therapy for chronic mesenterie ischemia. Arch Surg 132:613-618
12. Olin J W, Young J R, Graor R A et al (1990) The Changing Clinical Spectrum of Thromboangiitis Obliterans (Buerger's Disease). Circulation 82: IV-3-IV-8
13. Schellong S M, Rieger H (1999) Vaskulitiden. In: Classen M, Dierkesmann R, Heimpel H et al. (ed) Rationelle Diagnostik und Therapie in der Inneren Medizin. München, Wien, Baltimore: Urban & Schwarzenberg E9: 1-3
14. Teh L S, Manning J, Moore T et al (1995) Sustained release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumaiol 34: 636-641
15. Wilke W S, Hoffman G S (1995) Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am 21: 59-71
16. Zachariae H, Halkier-Sorensen L, Bjerring P et al (1996) Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venerol 76: 236-238